Phenotypic screening using iPSC-based human disease biology
- iPSC-derived human disease models that can be scaled to support HTS efficacy campaigns through robust bioprocessing/manufacturing
- Walk through a case study that demonstrates efficient iPSC-derived cardiomyocyte scale up, HTS assay development/validation, and a phenotypic HTS campaign of over 3,600 compounds from Ncardia’s “smart library”
Ncardia discussed the application of human iPSC-derived cell-based assays and high throughput screening for drug discovery and development. This approach enables researchers to access human disease-relevant biology earlier in the drug discovery process. They will explore a phenotypic drug screening platform composed of genetic and induced human iPSC-derived cardiac and neural disease models, controlled bioreactor-based manufacturing to enable batch sizes compatible with high-throughput screening (HTS), generation and validation of disease-relevant assays with clinically relevant readouts, and high-throughput screening using qualified disease assays.
Register
Speakers
Greg Luerman, PhD, Technical Director at Ncardia
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
Greg Luerman (PhD) is Technical Director at Ncardia. Following his graduate studies at the University of Louisville School of Medicine, Dr. Luerman earned a Michael J Fox Foundation postdoctoral fellowship within the Pfizer Neuroscience Research Unit where he lead bioassay development on a Parkinson’s disease therapeutic team. He moved on to establish a preclinical cardiac safety/tox and drug discovery assays at ChanTest (now Charles River). Now at Ncardia, Dr. Luerman oversees North American scientific operations.
Farbod Famili, Sr.Scientist, Assay development & High throughput at Ncardia
Farbod Famili (PhD) is Scientific Lead of assay development and high-throughput compound screening projects at Ncardia. His responsibilities include development and validation of assays in various cardiovascular cellular disease models using proprietary hiPSC-derived cardiomyocytes, high-throughput compound screening and target identification. Farbod has also developed expertise in application on of robotic liquid handling systems in 384 and 1536-well microplates.
